SecBot SecBot
Biotech Drug Report Generated Nov 10, 2026

pasritamig

ZYME·Zymeworks Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Phase 1/2 (first-in-human completed); Phase 3 ongoing
Time to market
Still in early-stage clinical development. Phase 1 results were just reported in November 2026, and Phase 3 trials are ongoing. If successful, potential approval is likely several years away (2029 or later).
Why 2/10
No hard dated catalyst is scheduled in the next ~12 months. Phase 1 results were just reported (November 8, 2026). Phase 3 trials are ongoing but no data readout date has been announced. As a JNJ asset, pasritamig is a tiny fraction of a ~$400B diversified healthcare company, so even a pivotal readout would have negligible impact on JNJ shares.
Actionable Insight NEUTRAL

Pasritamig's Phase 1 results were reported on November 8, 2026, showing a 73% PSA response rate. The next catalyst is the ongoing Phase 3 trial (pasritamig + docetaxel vs docetaxel alone in mCRPC), but no specific data readout date has been announced. For JNJ, this is a very early-stage asset in a massive pipeline, so even positive Phase 3 data would have a negligible impact on JNJ's share price.

Price Chart

Loading chart...

Executive Summary

Pasritamig (JNJ-78278343) is an investigational bispecific T-cell-engaging antibody being developed by Johnson & Johnson (JNJ) for metastatic castration-resistant prostate cancer (mCRPC). It targets KLK2, a protein found on prostate cancer cells, and directs the patient's T-cells to attack those cells. On November 8, 2026, J&J reported Phase 1 results showing a 73% PSA response rate (11 of 15 patients at the recommended regimen) for the combination of pasritamig and JNJ-9401 (a second bispecific targeting PSMA). The drug is advancing to Phase 3 testing. The filing hint linking pasritamig to Zymeworks (ZYME) is incorrect; pasritamig is wholly owned and developed by Johnson & Johnson, with no connection to Zymeworks.

How It Works

Pasritamig is a bispecific T-cell-engaging antibody, a type of immunotherapy. It works by binding to two targets simultaneously: one end grabs onto a protein called KLK2 (human kallikrein 2) found on prostate cancer cells, and the other end grabs onto CD3 receptors on the patient's own T-cells (immune cells). This forces the T-cells to get close to and kill the prostate cancer cells. It is being tested alone and in combination with JNJ-9401 (which targets a different prostate cancer protein called PSMA) to give a complementary immune signal.

Trial Status

Phase 1 first-in-human results for pasritamig + JNJ-9401 combination were reported on November 8, 2026, showing a 73% PSA response rate at the recommended Phase 2 regimen. A Phase 3 randomized open-label study of pasritamig + docetaxel vs docetaxel alone in mCRPC is ongoing (ASCO 2026 abstract). A Phase 1b/2 combination trial with GI Innovation's GI-102 is also underway.

The Two-Sided Case

▲ Bull Case4
Phase 1 results showed a 73% PSA response rate (11 of 15 patients at the recommended Phase 2 regimen), which is a strong early efficacy signal for a novel immunotherapy in a hard-to-treat cancer.
The combination of pasritamig (anti-KLK2) and JNJ-9401 (anti-PSMA) is a first-of-its-kind dual-antigen-targeted bispecific regimen designed to provide complementary T-cell activation signals.
Low rates of treatment-related adverse events were observed, and the regimen features every-six-week outpatient dosing designed for the community setting.
Phase 3 trials are already underway, including a randomized study of pasritamig + docetaxel vs docetaxel alone in mCRPC.
▼ Bear Case4
Phase 1 data is from a small, uncontrolled study (15 patients at the recommended regimen) and does not establish survival benefit or superiority over existing treatments.
The drug is still in early clinical development; most oncology candidates fail in later-stage trials.
JNJ faces intense competition in mCRPC from approved therapies including docetaxel, enzalutamide, abiraterone, and other novel immunotherapies.
As a JNJ asset, pasritamig represents a tiny fraction of a ~$400B diversified healthcare company, so even major trial outcomes would have negligible impact on JNJ shares.

Upcoming Catalysts

  • Phase 3 data readout for pasritamig + docetaxel vs docetaxel in mCRPC (no date announced)
  • Phase 1b/2 combination data with GI-102 (GI Innovation collaboration)
  • Additional Phase 1 monotherapy and combination data updates

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Zymeworks Inc. PRESS-RELEASE ZYME ·Originating report

Sources · 8

Hover a chip for the title
1 prnewswire.com2 rttnews.com3 msn.com4 rttnews.com5 ascopubs.org6 prnewswire.com7 prnewswire.com8 biz.heraldcorp.com